Hoth Therapeutics Announces Stock Offering and Warrants Sale

Hoth Therapeutics Inc. experienced a significant decline of 33.54% as it crossed below its 5-day SMA.

The company announced a direct offering of 2,857,144 shares at $0.70 each, expecting gross proceeds of approximately $2 million for general corporate purposes, including working capital. Concurrently, unregistered warrants were issued to purchase the same number of shares at an exercise price of $0.85, potentially raising an additional $2.4 million if fully exercised. This offering is managed by H.C. Wainwright & Co. and is expected to close around April 2, 2026, contingent upon customary closing conditions.

This stock offering reflects Hoth's strategy to enhance financial flexibility, although the market's positive performance may have contributed to the stock's decline due to sector rotation.